Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Half Of Breakthrough Designations Have Resulted In Approval
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(267)
•••
Comment by LaserStock29on Apr 27, 2022 10:32am
132 Views
Post# 34635417

RE:RE:Half Of Breakthrough Designations Have Resulted In Approval

RE:RE:Half Of Breakthrough Designations Have Resulted In ApprovalNope, I reject your suggestion, clearly you didn't read my links on Fast Track, Rolling Review and establishing a clear communication with FDA as we go

So that we dont have to wait 3 months to collect data on a USB and submit it all at once.. like a company without a Fast Track.

Please re-read the links. and update your posts accordingly.. Waiting 8 years for some actual progress.. 

Not to be kicked in the nuts on an annual that says oh we just applied please wait 60 new days...

Like the old days of Health Canada ... heres 75 more days...... then wait for reply 45 days.. etc are we really going to go through that again.



ScienceFirst wrote: So my suggestion of this morning that TLT can take 3 more months before applying, instead of rushing with unsufficient or not clear enough data.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities